fair enough - I think manufacturing shouldn’t be an issue. It clearly has the advantage in that area. I think it’s more the logistics and supply chain of the drug that will make it tricky to commercialise. It has a longer half life but it is still time sensitive.
Personally, it’s not something that I know too much about but that would definitely be something Pharma companies will look for as well as the manufacturing.
-
- There are more pages in this discussion • 364 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$3.91 |
Change
0.020(0.51%) |
Mkt cap ! $1.264B | |||
| Open | High | Low | Value | Volume |
| $3.87 | $4.16 | $3.84 | $22.81M | 5.683M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5599 | $3.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.95 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |